【摘要】：目的探討氯氮平與利培酮聯(lián)合治療難治性精神分裂癥(TRS)臨床效果。方法 100例難治性精神分裂癥患者按治療方案不同隨機(jī)分為觀察組和對照組,各50例。對照組給予氯氮平治療,觀察組給予氯氮平聯(lián)合利培酮治療,連續(xù)治療12周,對比兩組臨床治療效果、不良反應(yīng)發(fā)生率,用陽性與陰性癥狀(PANSS)量表評估治療前、治療2、4、8、12周后癥狀改善情況,用簡明健康調(diào)查量表(SF-36)評估治療前、治療12周后生活質(zhì)量變化情況。結(jié)果觀察組總有效率高于對照組(P0.05);治療2、4、8、12周后PANSS評分低于對照組(P0.05);治療12周后SF-36評分高于對照組(P0.05)。結(jié)論氯氮平聯(lián)合利培酮治療難治性精神分裂癥療效顯著,可改善其陽性及陰性癥狀。
[Abstract]:Objective to investigate the clinical effect of clozapine combined with risperidone in the treatment of refractory schizophrenia with (TRS). Methods 100 patients with refractory schizophrenia were randomly divided into observation group (n = 50) and control group (n = 50). The patients in the control group were treated with clozapine and risperidone for 12 weeks. The clinical effects and the incidence of adverse reactions were compared between the two groups. The (PANSS) scale for positive and negative symptoms was used to evaluate the treatment before treatment. The symptoms were improved after 8 and 12 weeks, and the quality of life was evaluated before and 12 weeks after treatment with the Concise Health Survey scale (SF-36). Results the total effective rate of the observation group was higher than that of the control group (P0.05), the PANSS score was lower than that of the control group at 2,4,8,12 weeks after treatment (P0.05), and the SF-36 score was higher than that of the control group after 12 weeks of treatment (P0.05). Conclusion clozapine combined with risperidone is effective in the treatment of refractory schizophrenia and can improve its positive and negative symptoms.
【作者單位】： 河北省第六人民醫(yī)院;
【基金】：河北省衛(wèi)生廳科研基金,編號:20120254
【分類號】：R749.3
，

本文編號：2436563